Retrospective Study of Introducing Suvorexant to Long-term Users of Benzodiazepines

Benzodiazepines (BZDs) are frequently used for insomnia, but the long-term use of BZDs is associated with adverse events such as dependence and withdrawal syndrome. Suvorexant (SUV), an orexin receptor antagonist, is a novel hyp-notic drug that has been shown to be effective for subjective measures of sleep onset and maintenance, safe, and well tolerated in clinical trials. In a long-term clinical trial, SUV discontinuation did not cause rebound insomnia or withdrawal symptoms, suggesting that it may be useful as an alternative drug in long-term users of BZDs. We retrospectively investigated the prescriptions when SUV was introduced to long-term users of BZDs. Sixty patients of long-term users of BZDs, who were prescribed SUV during January 2015 to December 2017, were analyzed. These patients were divided into the add-on group (n = 28) and the switching group (n = 32). The rate of SUV prescription continuation was 92.9 ％ in the add-on group, which was significantly higher ( P = 0.048) than 71.9 ％ in the switching group. The all adverse events rate was 32.1 ％ in the add-on group and 28.1 ％ in the switching group, and there was no significant difference between the two groups. This study revealed that in long-term users of BZDs, add-on and switching were equivalently selected as the method of introducing SUV. It was also suggested that the rate of SUV prescription continuation could be maintained higher in the add-on group than in the switching group.

• Publication year

  2021

• Venue

  Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)

• Publication date

  2021-03-10

• Fields of study

  Not labeled

• Identifiers
  DOI 10.5649/jjphcs.47.123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study

  2018cited by this paper
• A survey of the effects of ramelteon on benzodiazepine-dependence: Comparison between a ramelteon add-on group and a continuous benzodiazepine administration group.

  2018cited by this paper
• Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

  2017cited by this paper
• Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis

  2017cited by this paper
• Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

  2015cited by this paper
• Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

  2012cited by this paper
• Benzodiazepines revisited--will we ever learn?

  2011cited by this paper
• Insomnia: definition, prevalence, etiology, and consequences.

  2007cited by this paper
• Regular prescriptions for benzodiazepines: a cross-sectional study of outpatients at a university hospital.

  2006cited by this paper
• Cognitive Effects of Long-Term Benzodiazepine Use

  2004cited by this paper
• Primary insomnia: a risk factor to develop depression?

  2003cited by this paper
• Benzodiazepines with different half-life and falling in a hospitalized population: The GIFA study. Gruppo Italiano di Farmacovigilanza nell'Anziano.

  2000cited by this paper
• Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

  1999cited by this paper
• Drugs and Falls in Older People: A Systematic Review and Meta‐analysis: I. Psychotropic Drugs

  1999cited by this paper
• Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome

  1999cited by this paper
• Benzodiazepines revisited.

  1998cited by this paper
• The benzodiazepine withdrawal syndrome.

  1994cited by this paper
• Rebound insomnia: its determinants and significance.

  1990cited by this paper

• No citing papers are available for this paper.